|
|
|
|
|
|
|
|
|
|
|
22.10.25 - 09:01
|
AAX Biotech Announces Collaboration with Daiichi Sankyo to Evaluate Opti-mAb® Technology in Next-Generation Antibody Therapeutics (Cision)
|
|
|
Stockholm, Sweden, Oct 22, 2025 – Swedish biotech company AAX Biotech AB announces a collaboration with Daiichi Sankyo, one of the global leaders in antibody-drug conjugates (ADCs). The collaboration marks a significant milestone for AAX Biotech, underscoring the potential of its proprietary Opti-mAb[®] technology for innovative antibody therapeutics.
[AAX-Biotech-Daiichi-Sankyo-collaboration-Opti-mAb.png]
AAX Biotech pioneers innovative technologies that advance the development of next-generation antibody therapeutics. Its two platforms, Seqitope[®] and Opti-mAb[®], address key...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.09.25 - 08:30
|
Enhertu improved IDFS in early BC in DB-05 (Cision)
|
|
|
29 September 2025
Enhertu demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial in patients with high-risk early breast cancer following neoadjuvant therapy
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo's Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Results from the DESTINY-Breast05 and DESTINY-Breast11 trials
will be presented at ESMO 2025 in a Presidential...
|
|
|
25.09.25 - 23:48
|
XFRA: DIVIDEND/INTEREST INFORMATION - 29.09.2025 - JP3475350009 (XETRA)
|
|
|
Das Instrument D4S JP3475350009 DAIICHI SANKYO CO. LTD EQUITY wird cum Dividende/Zinsen gehandelt am 26.09.2025 und ex Dividende/Zinsen am 29.09.2025
The instrument D4S JP3475350009 DAIICHI SANKYO CO. LTD EQUITY has its pre-dividend/interest day on 26.09.2025 and its ex-dividend/interest day on 29.09.2025...
|
|
|
|
|
|
|
18.09.25 - 12:36
|
Immuto Scientific Announces $8M Seed 2 Financing and Daiichi Sankyo Collaboration to Uncover a New Class of Therapeutic Targets with Structural Surfaceomics (Business Wire)
|
|
|
Immuto Scientific unveils collaboration with Daiichi Sankyo to identify cancer‑specific cell‑surface targetsMADISON, Wis. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--#biotech--Immuto Scientific announced today the closing of an oversubscribed $8 million Seed 2 financing round and a drug discovery collaboration with Daiichi Sankyo, a global pharmaceutical company. Immuto Scientific is applying its AI-enabled structural surfaceomics platform to a new approach in drug discovery. Backed by the financing, the company will advance its internal oncology pipeline toward IND-enabling studies and extend the platform into additional areas such as immunology and inflammation.
“The greatest challenge in drug discovery today is not the lack of modalities; it's the shortage of truly novel, disease‑specific targets,” said Faraz A. Choudhury, Ph.D., co‑founder and CEO of Immuto Scientific. “The vast majority of drug targets overlap with healthy tissues, which drives toxicity and narrow therapeutic windows. Our dat...
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
